Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHST BioHarvest Sciences	$6.50 +1.1%	$6.11	$6.46 ▼ $7.38	$106.76M	0.8	17,601 shs	10,926 shs
CYCC Cyclacel Pharmaceuticals	$2.00 -9.1%	$4.06	$1.95 ▼ $49.34	$28.51M	0.52	104,885 shs	144,475 shs
TRML Tourmaline Bio	$16.56 +6.7%	$15.62	$11.56 ▼ $29.79	$425.34M	2.11	269,912 shs	211,009 shs
VERV Verve Therapeutics	$4.63 +7.2%	$4.78	$2.86 ▼ $9.31	$412.73M	1.82	1.85 million shs	2.96 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHST BioHarvest Sciences	0.00%	+0.93%	+15.04%	+12.46%	+649,999,900.00%
CYCC Cyclacel Pharmaceuticals	0.00%	+687.09%	-44.71%	-66.37%	-94.88%
TRML Tourmaline Bio	0.00%	+9.74%	+3.44%	+19.74%	+8.59%
VERV Verve Therapeutics	0.00%	+9.46%	+0.87%	-46.04%	-25.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	0.6519 of 5 stars	0.0	2.0	0.0	0.0	2.9	2.5	0.0
TRML Tourmaline Bio	2.2856 of 5 stars	3.5	3.0	0.0	0.0	1.9	2.5	0.0
VERV Verve Therapeutics	3.5386 of 5 stars	4.5	2.0	0.0	0.0	2.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHST BioHarvest Sciences	3.00	Buy	$13.67	110.26% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
TRML Tourmaline Bio	3.00	Buy	$49.33	197.91% Upside
VERV Verve Therapeutics	3.00	Buy	$25.75	456.16% Upside

Current Analyst Ratings Breakdown

Latest BHST, TRML, CYCC, and VERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
4/15/2025	VERV Verve Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $24.00
4/15/2025	VERV Verve Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
4/15/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $39.00
4/14/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $25.00
4/8/2025	BHST BioHarvest Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/25/2025	VERV Verve Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHST BioHarvest Sciences	$25.19M	4.24	N/A	N/A	($1.08) per share	-6.02
CYCC Cyclacel Pharmaceuticals	$43K	602.74	N/A	N/A	$0.57 per share	3.51
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.08 per share	N/A
VERV Verve Therapeutics	$59.61M	6.92	N/A	N/A	$7.31 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHST BioHarvest Sciences	-$12.56M	-$0.72	N/A	N/A	N/A	-76.65%	N/A	-85.16%	5/29/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$22.56M	-$56.00	N/A	∞	N/A	-18,150.00%	-1,901.11%	-188.23%	N/A
TRML Tourmaline Bio	-$42.12M	-$3.21	N/A	N/A	N/A	N/A	-20.97%	-20.56%	N/A
VERV Verve Therapeutics	-$200.07M	-$2.11	N/A	N/A	N/A	-807.65%	-35.23%	-27.65%	N/A

Latest BHST, TRML, CYCC, and VERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$7.80 million	$7.64 million
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A
4/2/2025	Q4 2024	CYCC Cyclacel Pharmaceuticals	-$4.64	-$5.28	-$0.64	-$0.33	$0.01 million	$0.01 million
3/31/2025	Q4 2024	BHST BioHarvest Sciences	-$0.12	-$0.17	-$0.05	-$0.17	$7.24 million	$7.17 million
3/13/2025	Q4 2024	TRML Tourmaline Bio	-$0.91	-$0.86	+$0.05	-$0.86	N/A	$0.04 million
2/27/2025	Q4 2024	VERV Verve Therapeutics	-$0.72	-$0.58	+$0.14	-$0.58	$3.94 million	$13.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	$0.15	7.50%	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest BHST, TRML, CYCC, and VERV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/28/2025	CYCC Cyclacel Pharmaceuticals		$2.40		4/29/2025	4/29/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHST BioHarvest Sciences	N/A	0.80	0.48
CYCC Cyclacel Pharmaceuticals	N/A	0.77	0.77
TRML Tourmaline Bio	N/A	40.33	40.33
VERV Verve Therapeutics	N/A	13.05	13.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHST BioHarvest Sciences	N/A
CYCC Cyclacel Pharmaceuticals	23.58%
TRML Tourmaline Bio	91.89%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
BHST BioHarvest Sciences	N/A
CYCC Cyclacel Pharmaceuticals	68.00%
TRML Tourmaline Bio	11.02%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
CYCC Cyclacel Pharmaceuticals	14	12.96 million	4.78 million	Optionable
TRML Tourmaline Bio	44	25.69 million	22.82 million	Optionable
VERV Verve Therapeutics	110	89.14 million	68.32 million	Optionable

BHST, TRML, CYCC, and VERV Headlines

Recent News About These Companies

VERVE-102: A single-course gene editing therapy for permanent inactivation of PCSK9

May 16 at 6:06 AM | bioworld.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Rating of "Buy" by Analysts

May 16 at 4:49 AM | marketbeat.com

'Unbelievably blessed': First custom CRISPR therapy alleviates worst of rare genetic disease for infant

May 15 at 2:12 PM | fiercebiotech.com

Jacobs Levy Equity Management Inc. Acquires 288,678 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

May 15 at 5:41 AM | marketbeat.com

Verve Therapeutics Shares Rise After Narrower-Than-Expected 1Q Loss

May 14, 2025 | marketwatch.com

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2025 | zacks.com

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

May 14, 2025 | globenewswire.com

LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight

May 10, 2025 | prnewswire.co.uk

Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Wednesday

May 9, 2025 | marketbeat.com

Verve Therapeutics Stock Short Interest Report | NASDAQ:VERV | Benzinga

May 8, 2025 | benzinga.com

Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges

May 7, 2025 | investing.com

Biotech Stocks Fall After FDA Names Vinay Prasad To Succeed Marks at CBER

May 7, 2025 | biospace.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Stock Position Lifted by BVF Inc. IL

May 6, 2025 | marketbeat.com

April 2025 Recap: Drug Pipeline Updates

May 5, 2025 | empr.com

PDT Partners LLC Sells 128,512 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

May 5, 2025 | marketbeat.com

‘Safer’ CRISPR: Base Editing Breaks Through in the Clinic as Beam, Verve Advance

May 5, 2025 | biospace.com

Susquehanna Fundamental Investments LLC Invests $1.64 Million in Verve Therapeutics, Inc. (NASDAQ:VERV)

May 3, 2025 | marketbeat.com

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Schonfeld Strategic Advisors LLC Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

May 2, 2025 | marketbeat.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by T. Rowe Price Investment Management Inc.

April 30, 2025 | marketbeat.com

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

April 29, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST, TRML, CYCC, and VERV Company Descriptions

BioHarvest Sciences NASDAQ:BHST

$6.50 +0.07 (+1.09%)

As of 05/16/2025 03:59 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$2.00 -0.20 (-9.09%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$2.04 +0.04 (+2.25%)

As of 05/16/2025 07:30 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Tourmaline Bio NASDAQ:TRML

$16.56 +1.04 (+6.70%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$16.56 0.00 (-0.03%)

As of 05/16/2025 07:23 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Verve Therapeutics NASDAQ:VERV

$4.63 +0.31 (+7.18%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$4.58 -0.04 (-0.97%)

As of 05/16/2025 07:56 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time